Pharmaceutical innovation: The gap between knowledge, attitude, and perceptions among pharmacists and final-year pharmacy students

Mohanad Odeh¹, Rami Amer², Abdel Qader Al Bawab², Mary-Carmel Kearney¹, Karem H. Alzoubi⁴,⁵*

¹Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan.
²Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
³School of Pharmacy, Queens University Belfast, Belfast, United Kingdom.
⁴Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.
⁵Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.

ARTICLE INFO
Received on: 01/03/2022
Accepted on: 30/07/2022
Available Online: 04/10/2022

Key words: Innovation, entrepreneurship, knowledge, attitude, perception, pharmacists, pharmacy students.

ABSTRACT
Recently, there has been an increasing interest in innovative business development. Nevertheless, in the pharmacy practice field, there seems to be a gap in perceptions, attitudes, and knowledge about innovation between practicing pharmacists and academia. This study explores this gap and aspects of pharmaceutical innovation in Jordan comparing pharmacists and last-year pharmacy students. A validated (r² = 0.74) and reliable (Pearson’s r = 0.88) online questionnaire was designed to assess and compare knowledge, attitude, and perceptions about pharmaceutical innovation. A total of 397 participants (215 pharmacy students and 182 pharmaceutical professionals) responded. Compared with 50% of the pharmacists, only 32.1% of the students claimed that they knew the differences between pharmaceutical innovation, discovery, invention, and entrepreneurship [x² (2) = 14.238, p = 0.001; Cramer’s V = 0.189]. Pharmacists demonstrated a higher level of trust in the innovative website design for their institution compared with students (25.3% vs. 16.3%, p < 0.001, Cramer’s V = 0.327). However, 60% of the students did not know the innovative design standards for websites, while the corresponding percentage was 37% for the pharmacists (p < 0.001; Cramer’s V = 0.327). The majority of the students were interested in pharmaceutical innovation (81.9%). Unfortunately, 76.3% never studied about innovation in their pharmacy curricula. Similarly, most pharmacists (76.4%) considered adopting innovation, but only 30% had a concrete plan. For the field where pharmacists aim to innovate in the next 5 years, new pharmaceutical services were the dominant field (34.6%). Despite a positive attitude and perception, pharmacists and pharmacy students expressed poor knowledge about innovation. Policies to enhance awareness about innovation and professional educational tools should be implemented.

INTRODUCTION
Background and definition
Innovation within the pharmaceutical industry continues to draw considerable interest from industry and academia. This is not surprising given the important impact of innovation on various aspects of life (Baregheh et al., 2009). From an economic perspective, innovation has contributed to improved quality of life in many countries, which is reflected as improvement in their economies (Atkinson & Wial, 2008). Despite this interest, many pharmacists still find it challenging to differentiate among
terms such as pharmaceutical innovation, invention, discovery, and entrepreneurship. Innovation may be defined as a new idea, creative thoughts, or new imaginations in the form of a device or a method (Arruda, 2016).

Pharmacy is an area that has had a significant share of innovation over the years with many pharmacists, working in various sectors, contributing to the development of new and innovative ideas, products, and services. Pharmaceutical innovations range from the design and discovery of new medicines to novel methods of service delivery, all to enhance patient care (Morgan et al., 2008). It can be said that the discovery, development, production, and delivery processes that increase the availability of medical products and people’s access to them summarize the concept of pharmaceutical innovation (Berger et al., 2016).

Opportunities for innovation within clinical pharmacy and pharmacy practice sectors are many. Examples of previously reported innovations in these areas include innovation focused on clinical performance and regularly monitoring performance data, implementing and prioritizing an appointment-based medication synchronization program, offering patient-centered care by directly delivering services to customers, providing electronic services, and actively participating in the local and greater pharmacy community.

Difference between innovation, invention, discovery, and entrepreneurship

Terms of entrepreneurship and innovation complement each other. However, entrepreneurship is simply the design and launch of new business; innovation is the process of creating new ideas that contribute to business development. In other words, innovation is considered a tool for entrepreneurship (Soriano & Huarng, 2013). There is also a great convergence between the terms “invention” and “innovation”; yet, invention involves the process of creating a new thing that did not exist before, whether it was a product or service, while innovation is to find an idea to introduce this invention into practice (Toner & Tompkins, 2008). Discovery is defined as the process by which new things are known that were not previously known, while innovation comes to transform these discoveries into useful products (Sams-Dodd, 2005).

Innovative design can also be used to describe websites. Thus, in the present digital environment, pharmaceutical institutions should be aware of their websites. In that respect, the following aspects are used to assess the level of innovative design: minimalism, diversity, immersive 3D elements, responsive design, dark mode, micro-interactions, video content, mixing photography with graphics, attractiveness, and fast loading (Shneiderman & Leavitt, 2006).

Pharmaceutical innovation worldwide

Pharmaceutical research and development have traditionally been dominated by multinational companies in the United States and Europe. More recently, other countries such as China and Brazil have developed their pharmaceutical industries to compete in the global pharmaceutical market (Akkari et al., 2016). The rate of technological progress, based on innovation, is a key factor in determining the rate of economic growth. For example, in the United States of America, the increased longevity resulting from pharmaceutical innovation has elevated national wealth by an estimated $3.2 trillion annually (Lichtenberg, 2010). The economic benefits of innovation are not the only stimulus for increased innovative interest, but the positive consequences on population health (Lichtenberg et al., 2017) and reduced mortality and improved quality of medical services (Lichtenberg, 2014a) continue to drive change.

Factors promoting pharmaceutical innovation and obstacles

Many factors influence pharmaceutical innovation both globally and within a country. One of the key promoting factors for innovation is the legislative change, for example, amending legislation to facilitate the innovation process. This may involve modification of some of the existing systems to increase access to larger marks, such as exclusive rights and intellectual property. Providing governmental and societal support for pharmaceutical innovations also stimulates the development of innovative practices. This requires an initial direct investment from governments and societies, reduced tax measures or rescheduling of finances, and so forth. It is hoped that the initial investment will generate future health and economic benefits. Access to expert knowledge and other resources also helps to promote innovation and reduces the risk of failure (Rovira, 2009). Many other factors might also promote innovation, such as proper education, continuous development and training, and the availability of infrastructure. On the other hand, obstacles that hinder innovation include lack of financial investment and support, lack of experience in the field of innovation, and legislative processes that convolute the process (Strobel & Kratzer, 2017).

Innovation in Jordan

Although Jordan is a small country suffering from a scarcity of natural resources with a small population (Dandani, 2011), a large part of its economy depends on industry, where it contributed around 11% of the GDP in 2009 (Kreishan, 2010). The pharmaceutical industry is considered one of the most important pillars of the Jordanian economy (Al-Wazayf & Albsoul-Younes, 2005). Jordanian pharmaceutical production is one of the largest in the Middle East, where Jordanian pharmaceutical companies export more than 70% of their products to 65 countries around the world (Alawi & Alabbadi, 2015). Recently, many business incubators were established in Jordanian universities and public–private institutions. Examples include Umniah and Zinc Business Incubators and iPark, which may play an important role in supporting emerging innovative ideas. At least three annual national competitions have been created to encourage healthcare providers and students to create and lead innovative projects: Hakeem Academy Annual Competition (Hakeem Academy, 2020), Crown Prince Competition for the Best Government Application (The Crown Prince Foundation, 2018), and Be the Solution Competition. However, only the last one solely targets the pharmacy sector (The Arab Innovation Network, 2020). The private sector also funds many competitive financial investments, often advertised via social media platforms (Al Bawab et al., 2018).
Even though the pharmaceutical industry and pharmaceutical care are some of the national Jordanian priorities, almost all innovations in Jordan are related to business administration and computer sciences (Obeidat et al., 2016). Pharmaceutical innovation in Jordan faces many problems; for example, the rules and regulations are not consistent, the financial support is less than needed for such innovation, and sometimes experts who can turn theoretical context into practicalities are not present. Accordingly, the new product development process in the Jordanian pharmaceutical sector is considered highly risky and difficult (Ghanajeh et al., 2015). The role of pharmaceutical innovations in pharmaceutical practice can be strengthened by developing cooperation between pharmacy practice and academia. This should help to implement innovations that more closely align with the needs of the local community and therefore creates an environment that supports the innovations. (Alsharif, 2019) Ultimately it is hoped that this will result in improved patient outcomes. However, upon review of the curriculum of 17 pharmacy schools in Jordan, we could not find a special module within pharmacy schools that targets innovation and entrepreneurship in pharmacy. To the best of our knowledge, this is the first research paper that aims to investigate the knowledge, attitude, and perceptions (KAP) of pharmaceutical innovation among Jordanian pharmacists and final-year bachelor’s pharmacy students.

METHOD

Study design and settings

This study was carried out through an online validated and reliable questionnaire by using a Google Forms template to explore the KAP toward pharmaceutical innovation among pharmacists and final-year pharmacy students in Jordan. Data collection was carried out during the period from February to August 2020 in Amman, Jordan. The questions were categorized in three sections: Demographic characteristics shared questions, then tailored tracks for Bachelor of Pharmacy Students, but not Doctor of Pharmacy (PharmD) finally tailored track for pharmacists.

The shared questions were designed to investigate five domains: first, the definitions of pharmaceutical innovation, pharmaceutical discovery, pharmaceutical invention, and pharmaceutical entrepreneurship; second, assessment of knowledge and perception of the innovative design of the websites for the responder’s institutions and other Jordanian public institutions (Jordanian Food and Drug Administration “JFDA,” Ministry of Health and the Jordanian Pharmacist Association); third, perception of government and private sector support for pharmaceutical innovation and knowledge about the available fund in Jordan; fourth, perception of the future of pharmaceutical innovation in the next 10 years in addition to the expected impact on both the health and economic sectors; fifth, perception of comparing innovation among other countries in the Middle East in terms of presence and acceptance of innovations within the pharmacy fields. Tailored tracks were designed to take into consideration different attitudes among students and pharmacists, in addition to identifying gaps between attitudes and knowledge.

Questionnaire development and face validity

The questionnaire was designed in the English language. The preliminary version was circulated to a pilot group for review and face validation (Bolarinwa, 2015). The pilot group consisted of 20 members: 6 pharmacy professional innovators (entrepreneurs) who manage innovative business related to pharmacy, 3 academic associate professors in pharmacy practice, 5 undergraduate pharmacy students, and 6 postgraduate pharmacy students.

Feedback from the pilot group to enhance face validity was used to modify the final version of the questionnaire. It was then translated into Arabic as all the respondents were native Arabic speakers. The questionnaire was translated by two independent bilingual translators who were native Arabic speakers and proficient in English. One of these translators (Translator 1: T1) was aware of the underpinning concepts and objectives of the questionnaire, while the other translator (Translator 2: T2) was not. This was useful to elicit unexpected meanings from the original version and helped to detect errors and divergent interpretations of ambiguous items in the original tool and to ensure the translation was bias-free (Degroot et al., 1994).

Construct validity and reliability measures

The assessment tool used in this study was a questionnaire designed by the research investigators based on previous studies with some modifications. To confirm the construct validity (Bolarinwa, 2015; Heale & Twycross, 2015; Taherdoost, 2016) of the questionnaire, the association between the scale items (correlation matrices) was evaluated. The correlation coefficient ($r^2$) was 0.74, which permitted the construct validity. Reliability was confirmed by Cronbach’s alpha and Pearson’s r analysis. The questionnaire was tested on a pilot sample of 40 responders. Responders were contacted first and 15 days later to complete the questionnaire again (pretest/posttest reliability was carried out) to justify moving forward with a large-scale pilot test.

The questionnaire was overall reliable regarding overall internal consistency and stability, which was estimated using the coefficient alpha (Cronbach’s alpha $= 0.62$) and test-retest reliability (Pearson’s $r = 0.88$). The coefficient alpha result reflects acceptable internal consistency. The results of the stability coefficient indicated stronger test-retest reliability, reflecting that the measurement error of the questionnaire is less likely to be attributable to changes in the individuals’ responses over time (Bercholdt, 2016).

Ethical consideration

The protocol of this study was approved by the IRB of the Hashemite University, Jordan (reference number: 4/2019/2020, 22nd Jan 2020 – No.4). Eligible responders were those participants who wanted to voluntarily respond to the questionnaire. The questionnaire was distributed using social media platforms (Facebook) and WhatsApp application through the study panel members.

It was clarified that responses would be treated confidentially and anonymously. It was illustrated that no personal identifier where possible in the questionnaire. Moreover, it was stated that responders at any time during the questionnaire have the free choice to withdraw from answering, as their participation is voluntary. Accordingly, participants who submitted the response with their answers were considered to have given informed consent for their participation. At the end of the pilot group trial and
modifications, the final form of the questionnaire was published as an online Google Form.

Sample size calculation

The target population of the current study was divided into two substrata based on specialty and education, i.e., working pharmacists versus students. As recommended by Taherdoost (2017) and carried out by the sample size calculator (Select Statistical Consultants United Kingdom, 2019), the representative sample size for the pharmacy discipline (actual pharmacists and final-year pharmacy students) was calculated to be 381 participants providing a 95% confidence interval and a 5% margin of error for a population of no more than 40,000 pharmacists according to the Jordanian Pharmacists Association.

Statistical analytical interpretation

A chi-squared test of association was conducted between answers to the questions within the survey and the specialty of responders, according to the following hypothesis: The null hypothesis is $H_0$: there is no association relationship between answers and specialty (final-year pharmacy students vs. pharmacists). The alternative hypothesis is $H_1$: an association relationship exists between answers and specialty. The measure of effect size and magnitude and strength of association of a nominal-by-nominal relationship was assessed by the phi ($\phi$) coefficient when having two dichotomous variables or Cramer’s V coefficient when having more than two dichotomous variables. The following “crude estimate” of absolute value of the coefficient was considered for interpreting the strengths of relationships: negligible relationship ($<0.19$), weak relationship ($0.2–0.29$), and moderate relationship ($0.30–0.39$) (McHugh, 2013).

RESULTS

Descriptive results

A total of 397 participants answered the questionnaire. Almost 54.2% were final-year bachelor of pharmacy students, and 45.8% were pharmacists. Unlike students, pharmacists had an approximate balance gender distribution, i.e., 44% female vs. 56% male. In comparison, 80% of the students who responded were female. Most of the participating pharmacists worked in the private sector (84.6%). The participants worked in a variety of positions as follows: officers in drug stores (15.4%), medical representatives (19.8%), management (23.6%), practicing community pharmacists (30.2%), and academics (2.7%). There were other categories also (8.2% included freelancers, pharmacists working in health media, manufactories, quality assurance, sports trainers, consultation services, and insurance companies).

Knowledge about terminology

Only 32.1% of the students and 50% of the pharmacists claimed that they knew the differences between the terms (discovery, invention, innovation, and entrepreneurship). Such a gap in knowledge between pharmacists and students was statistically significant [$X^2(2) =14.238$, $p = 0.001$; Cramer’s V = 0.189]. The most recognized term seemed to be “pharmaceutical discovery,” where it was known to 83.7% of the students and 80.8% of the pharmacists. The most problematic term was “pharmaceutical entrepreneurship,” where it was known to only 27.4% of the students and 30.2% of the pharmacists. More details are presented in Table 1.

Perceptions

Pharmacists who had websites demonstrated a higher perceived significant level of trust in the innovative design of their institution’s website, with a moderately strong association, 25.3% who claimed to have such innovative design versus 16.3% for the students ($p < 0.001$, Cramer’s V = 0.327). However, almost one-fifth of the pharmacists’ institutions did not have a website, and almost half of the students were not sure about their answers. Surprisingly, approximately 60% of the students did not know the innovative design standards for websites compared with 37% of the pharmacists. The gap in such knowledge was statistically significant with a moderately strong association ($p < 0.001$; Cramer’s V = 0.327, $p < 0.001$).

Students expected that the JFDA has a better implementation of innovative website design (48.8%) compared with the Ministry of Health (30.2%) and the Pharmacists Association (24.2%). A similar pattern was also perceived by pharmacists; their evaluation was 36.8%, 23.6%, and 20.9%, respectively. It is noteworthy that the most common reported answer was “not sure” when responders were asked about the innovative design of the three national institutions, as illustrated in Table 2.

Interestingly, both students and pharmacists showed a similar distribution of their perception of governmental or private support to pharmaceutical innovation projects, where 64.7% of the students answered with “no support is provided to innovation projects” and 64.3% of the pharmacists had the same answer. Similarly, both groups were not familiar with available grants to support innovative projects; only 26.5% of the students and 22.0% of the pharmacists knew about relevant funding bodies in Jordan. Despite students’ interest in innovation, only 18.1% were aware of the annual national competition for pharmaceutical innovation, as further detailed in Table 3.

Both groups demonstrated positive and comparable perceptions toward evolving innovations over the next 10 years; 76.7% of the students and 67.0% of the pharmacists thought that it would evolve in that period. Almost all students (94%) and pharmacists (94%) thought that pharmaceutical innovation would contribute to improving health sector services with a similar attitude found for expected economic benefits. Details are illustrated in Table 3.

Participants were asked about their opinion about pharmaceutical innovation in Jordan compared to the Middle East region and the extent to which the Jordanian market accepts pharmaceutical innovations compared to the Middle East region. The assessment of Jordanian pharmaceutical innovation compared to the Middle East was almost similar across the 10-point ranking scale for both the pharmacists and students. The vast majority in both groups showed neutral assessment, ranging from 4 to 7. Similar findings were illustrated again in the acceptance of the Jordanian market for pharmaceutical innovations when compared to the markets of the Middle East region, as shown in Figures 1 and 2.
Table 1. Knowledge about the definition of innovation-related terms.

| Question | Answers | Students | Pharmacists | Total | Statistic chi-squared | p value | Cramer’s V |
|----------|---------|----------|-------------|-------|-----------------------|---------|------------|
| Do you know what the difference between the following terms “Discovery” is, “Invention”, “Innovation”, and “Entrepreneurship”? | Yes | 69 | 91 | 160 | 14.238 | 0.001 | 0.189 |
| | No | 43 | 21 | 64 | 47.9% | 38.5% | 43.6% |
| | Not sure | 103 | 70 | 173 | 40.0% | 33.5% | 0.692 |
| | Total | 215 | 182 | 397 | 100.0% | 100.0% | 100.0% |
| Did you know that the term “Pharmaceutical Invention” is used to describe the process by which an entirely new pharmaceutical product is created and introduced to the medical practice? | Yes | 116 | 110 | 226 | 54.0% | 60.4% | 56.9% |
| | No | 75 | 53 | 128 | 34.9% | 29.1% | 32.2% |
| | Not Sure | 24 | 19 | 43 | 11.2% | 10.4% | 10.8% |
| | Total | 215 | 182 | 397 | 100.0% | 100.0% | 100.0% |
| Did you know that the term “Pharmaceutical Entrepreneurship” is defined as the process of designing, launching, and managing new pharmaceutical businesses and bearing their risks in the hope of financial profit? | Yes | 59 | 55 | 114 | 27.4% | 30.2% | 28.7% |
| | No | 126 | 109 | 235 | 58.6% | 59.9% | 59.2% |
| | Not Sure | 30 | 18 | 48 | 14.0% | 9.9% | 12.1% |
| | Total | 215 | 182 | 397 | 100.0% | 100.0% | 100.0% |
| Did you know that the term “Pharmaceutical Discovery” is defined as the process by which new drug compounds are discovered, not previously discovered? | Yes | 180 | 147 | 327 | 83.7% | 80.8% | 82.4% |
| | No | 16 | 25 | 41 | 7.4% | 13.7% | 10.3% |
| | Not Sure | 19 | 10 | 29 | 8.8% | 5.5% | 7.3% |
| | Total | 215 | 182 | 397 | 100.0% | 100.0% | 100.0% |
| Did you know that the term “Pharmaceutical Innovation” is defined as any new idea or group of creative ideas that contribute to health advancement? | Yes | 128 | 124 | 252 | 59.5% | 68.1% | 63.5% |
| | No | 60 | 41 | 101 | 27.9% | 22.5% | 25.4% |
| | Not Sure | 27 | 17 | 44 | 12.6% | 9.3% | 11.1% |
| | Total | 215 | 182 | 397 | 100.0% | 100.0% | 100.0% |

Atitudes: student-tailored questions

Students were asked about their interest in pharmaceutical innovation, whether they had studied pharmaceutical innovation during their university studies, and whether they knew of competitive funding bids related to innovation in Jordan. Most of the students were interested in the field of pharmaceutical innovation (81.9%). Despite this, 76.3% of the responders did not study pharmaceutical innovation during their bachelor’s program, where 55.8% of them denied any studies and 20.5% were not sure. Only 18.1% of the students confirmed their knowledge about the innovation competition.

Pharmacist-tailored questions

Approximately 32% of the pharmacists considered their work unrelated to the field of innovation, but almost one-quarter planned to implement innovative practices in the next 5 years. Those who worked in innovation were in a variety of roles, including pharmaceutical services and tools (18.1%), medication marketing (34.6%), patents (0.5%), and research and development in the pharmaceutical industry (2.7%). New pharmaceutical services were the dominant area (34.6%) in which pharmacists hope to innovate over the next 5 years. Results are shown in Table 4. Even though most pharmacists (76.4%) were

...
thinking of adopting innovation into their field of work, only 30% of them had a solid plan for such adoption (Table 5). The majority of the pharmacists believed financing pharmaceutical innovation was an impediment to progress in the area of innovation (89%). Two-thirds (66.5%) of the workers did not believe that there was a problem with the workforce and tools, but they believed there were difficulties in making changes to the system. Most pharmacists believed that laws and regulations were an impediment to progress in this area (75.8%). About 70% of the pharmacists believed that fears about investment in Jordan hinder progress in the field of pharmaceutical innovation. High taxes were perceived by 83% of the pharmacists as a factor preventing pharmaceutical innovation development. Surprisingly, almost 73.5% of the students and 78% of the pharmacists were not aware of the funding bodies in Jordan and that such bodies may support innovation and entrepreneurship.

**DISCUSSION**

The present research aimed to assess knowledge, attitude, and perceptions about pharmaceutical innovation in Jordan. The methodology was based on investigating and comparing results

| Question                                                                 | Answers                          | Students | Pharmacists | Total | Statistic chi-squared | p value | Cramer’s V |
|-------------------------------------------------------------------------|----------------------------------|----------|-------------|-------|------------------------|---------|------------|
| Do you think that the website of your organization meets the criteria of innovative design? | Yes                              | 35       | 46          | 81    | 42.566                 | p < 0.001 | 0.327      |
|                                                                         | No                               | 68       | 45          | 113   |                        |         |            |
|                                                                         | Not sure                         | 103      | 50          | 153   |                        |         |            |
|                                                                         | Total                            | 215      | 182         | 397   |                        |         |            |
| Did you know that the innovative design standards for websites include 3D elements, download speed, simplicity, and diversity? | Yes                              | 73       | 84          | 157   |                        |         |            |
|                                                                         | No                               | 125      | 67          | 192   |                        |         |            |
|                                                                         | Not sure                         | 17       | 31          | 48    |                        |         |            |
|                                                                         | Total                            | 215      | 182         | 397   |                        |         |            |
| Do you think that the pharmacist association takes into account the criteria of innovation in designing its websites? | Yes                              | 52       | 38          | 90    |                        |         |            |
|                                                                         | No                               | 59       | 84          | 143   |                        |         |            |
|                                                                         | Not sure                         | 104      | 60          | 164   |                        |         |            |
|                                                                         | Total                            | 215      | 182         | 397   |                        |         |            |
| Do you think that the Jordanian Food and Drug Administration takes into account the criteria of innovation in designing its websites? | Yes                              | 105      | 67          | 172   |                        |         |            |
|                                                                         | No                               | 37       | 58          | 95    |                        |         |            |
|                                                                         | Not sure                         | 73       | 57          | 130   |                        |         |            |
|                                                                         | Total                            | 215      | 182         | 397   |                        |         |            |
| Do you think that the Ministry of Health takes into account the criteria of innovation in designing its websites? | Yes                              | 65       | 43          | 108   |                        |         |            |
|                                                                         | No                               | 37       | 66          | 103   |                        |         |            |
|                                                                         | Not sure                         | 113      | 73          | 186   |                        |         |            |
|                                                                         | Total                            | 215      | 182         | 397   |                        |         |            |
between working pharmacists and final-year bachelor of pharmacy students. The current study is the first in Jordan to assess such aspects.

Pharmaceutical innovations play a vital role in improving the health level and positively impacting the lives of individuals, as discussed in a study by Lichtenberg (2014b). In another study, Berger et al. (2016) indicated the significant role that pharmaceutical innovation plays in the economic growth of economically vulnerable African countries. Another study by Lichtenberg (2013) emphasized that increased life expectancy as a result of pharmaceutical innovation is an integral part of the economic growth of a country. The results of the current study are consistent with global attitudes

| Question                                                                 | Answer          | Students | Workers | Total | Statistic chi-squared | p value  | Cramer’s V |
|-------------------------------------------------------------------------|-----------------|----------|---------|-------|------------------------|----------|------------|
| Do you think that pharmaceutical innovation projects get support, whether through the governmental or private sectors? | Yes             | 13       | 15      | 28    |                        |          |            |
|                                                                        | No              | 139      | 117     | 256   | 0.791                  | 0.673    | 0.045      |
|                                                                        | Not sure        | 63       | 50      | 113   |                        |          |            |
|                                                                        | Total           | 215      | 182     | 397   |                        |          |            |
| Are there grants to support innovation in Jordan?                       | Yes             | 57       | 40      | 97    |                        |          |            |
|                                                                        | No              | 119      | 114     | 233   | 2.165                  | 0.339    | 0.074      |
|                                                                        | Not sure        | 39       | 28      | 67    |                        |          |            |
|                                                                        | Total           | 202      | 171     | 373   |                        |          |            |
| Do you think that more attention to pharmaceutical innovation will contribute to improving the health sector? | Yes             | 202      | 94.0%   | 94.0% |                        |          |            |
|                                                                        | No              | 5        | 5.0%    | 10    | 0.120                  | 0.942    | 0.017      |
|                                                                        | Not sure        | 5        | 2.3%    | 2.5%  |                        |          |            |
|                                                                        | Total           | 215      | 100.0%  | 100.0%|                        |          |            |
| Do you think that more attention to innovation in the pharmaceutical contributes to improving the economic sector? | Yes             | 198      | 94.0%   | 94.0% |                        |          |            |
|                                                                        | No              | 6        | 5.1%    | 15    | 2.594                  | 0.273    | 0.081      |
|                                                                        | Not sure        | 11       | 5.1%    | 15    |                        |          |            |
|                                                                        | Total           | 215      | 100.0%  | 100.0%|                        |          |            |
| What is your expectation for the field of pharmaceutical innovation in Jordan during the next ten years? | It will not change | 30       | 14.0%   | 68    | 5.710                  | 0.127    | 0.120      |
|                                                                        | I’m not sure    | 17       | 7.9%    | 33    |                        |          |            |
|                                                                        | Total           | 165      | 76.7%   | 287   |                        |          |            |
|                                                                        | Will back off   | 3        | 1.4%    | 9     |                        |          |            |
|                                                                        | Total           | 215      | 100.0%  | 397   |                        |          |            |
| Are there competitions related to pharmaceutical innovation in Jordan? | Yes             | 39       | 18.1%   | NA    | NA                     | NA       | NA         |
|                                                                        | No              | 125      | 58.1%   | NA    | NA                     | NA       | NA         |
|                                                                        | Not sure        | 51       | 23.7%   | NA    | NA                     | NA       | NA         |

Berger et al. (2016) indicated the significant role that pharmaceutical innovation plays in the economic growth of economically vulnerable African countries. Another study by Lichtenberg (2013) emphasized that increased life expectancy as a result of pharmaceutical innovation is an integral part of the economic growth of a country. The results of the current study are consistent with global attitudes.
that participants have a positive perception of pharmaceutical innovation and its potential for economic benefits.

A gap in knowledge around innovative terminology was identified as most respondents did not know the differences among the terms “innovation,” “invention,” “discovery,” and “entrepreneurship.” Moreover, most workers who participated in the study wanted to introduce innovation in their field of work, but 70% did not have a clear plan for that purpose. This may be attributed to

**Figure 1.** Perceived assessment of the development of Jordanian pharmaceutical innovation, where scale 1 means very poorly developed and 10 means excellent development. $X^2(9) = 8.651, p = 0.470$, Cramer’s $V = 0.148$.

**Figure 2.** Perceived acceptance of the Jordanian market for pharmaceutical innovations, where 1 means very poor and 10 means excellent. $X^2(9) = 9.462, p = 0.396$, Cramer’s $V = 0.154$. 
Table 4. Tailored demographics for pharmacists.

| Question                                           | Answer                  | Pharmacist | Percentage |
|----------------------------------------------------|-------------------------|------------|------------|
| What is your work sector?                          | Non-profit organizations | 1          | 0.5%       |
|                                                    | Public sector           | 19         | 10.4%      |
|                                                    | Private sector          | 154        | 84.6%      |
|                                                    | Other than that         | 8          | 4.4%       |
|                                                    | Total                   | 182        | 100%       |
|                                                    | Community pharmacist    | 87         | 47.8%      |
|                                                    | Pharmaceutical marketing| 57         | 31.3%      |
|                                                    | Research and development| 7          | 3.8%       |
| What kind of work do you do?                       | Consulting and training | 3          | 1.6%       |
|                                                    | Industry                | 2          | 1.1%       |
|                                                    | Other                   | 26         | 14.3%      |
|                                                    | Practicing pharmacist   | 55         | 30.2%      |
|                                                    | Manager                 | 43         | 23.6%      |
|                                                    | Medical representative  | 36         | 19.8%      |
| What is your role in the work?                    | Officer                 | 28         | 15.4%      |
|                                                    | Academic                | 5          | 2.7%       |
|                                                    | Other                   | 15         | 8.2%       |
|                                                    | Total                   | 182        | 100%       |
|                                                    | Medication marketing    | 63         | 34.6%      |
|                                                    | Pharmaceutical services and tools | 33     | 18.1%      |
| Regarding your current business activity, what does it relate to areas of innovation? | Research and development in the pharmaceutical industry | 5       | 2.7%       |
|                                                    | Patents                 | 1          | 0.5%       |
|                                                    | I do not work in innovation | 58     | 31.9%      |
|                                                    | Other                   | 22         | 12.1%      |
|                                                    | Total                   | 182        | 100%       |
|                                                    | New pharmaceutical services | 73     | 53%        |
|                                                    | Introduce new products  | 27         | 19%        |
| If you plan to introduce pharmaceutical innovations over the next five years, in which area of the following do you plan? | New or improved pharmaceutical processes and tools | 11       | 4%         |
|                                                    | Innovative improvements to previous products | 6       | 3.3%       |
|                                                    | Other                   | 22         | 16%        |
|                                                    | Total                   | 139        | 100%       |

Table 5. Innovation and work position.

| Question                                           | Manager | Practicing pharmacist | Medical representative | Officer | Academic | Other | Total |
|----------------------------------------------------|---------|-----------------------|------------------------|---------|----------|-------|-------|
| Are you thinking about bringing innovation to your business work position? | Yes     | 39                    | 39                     | 24      | 19       | 5     | 13    | 139   |
|                                                    | No      | 4                     | 16                     | 12      | 9        | 0     | 2     | 43    |
|                                                    | Total   | 43                    | 55                     | 36      | 28       | 5     | 15    | 182   |
| Do you have a clear plan to bring innovation into your business work position? | Yes     | 14                    | 10                     | 6       | 7        | 2     | 4     | 43    |
|                                                    | No      | 25                    | 29                     | 18      | 12       | 3     | 9     | 96    |
|                                                    | Total   | 39                    | 39                     | 24      | 19       | 5     | 13    | 139   |
insufficient content about innovation during university studies and the lack of a program of continuous learning after graduation.

The present study confirmed the importance and challenges with regard to the financial investment needed for pharmaceutical innovations; such perception is consistent with the literature (Berger et al., 2016; Sampat and Lichtenberg, 2011). The high cost of pharmaceutical innovation is one of the most critical problems (Dubois et al., 2015). The results of the current study are consistent with this conclusion and confirm that the high financial cost prevents pharmaceutical innovation in Jordan. Surprisingly, only 26.5% of the students and 22.0% of the pharmacists knew about funding bodies in Jordan to support innovative entrepreneurship. This could be addressed through strategic advertisement and awareness campaigns.

Lack of experience, lack of qualified workforce, legislation, and laws were perceived to hinder progress in innovation (Atkinson & Wial, 2008). The results of this study confirm that laws and legislation can hinder progress in the field of pharmaceutical innovation. Moreover, only 23.7% of the students in the present study claimed to receive education about innovation, and almost 70% of the pharmacists wanted to adopt innovation but had no plan for such adoption.

In addition to the crucial need for training at the undergraduate and postgraduate levels, it seems that amending legislation and laws to facilitate the innovation process, providing governmental and societal support for pharmaceutical innovations, and using experts to avoid the risk of failure—as much as possible—are among the leading and fundamental solutions to problems of hindering progress in the field of pharmaceutical innovation (Rovira, 2009).

A few limitations may have an impact on the study outcomes. First, using a self-reported questionnaire in data collection means that answers by participants could not be accurately estimated due to personal bias, which may limit the generalizability of the findings. Second, due to digital means of distributing the survey, many questions had been modified or canceled to keep the questionnaire acceptable and avoid being too long. Also, we could not estimate the response rate as the study questionnaire was distributed via open social media platforms. Third, the sample was only final-year pharmacy students and pharmacists who were able to respond by digital means. Accordingly, pharmacists who had limited access to the Internet might generate different results. Fourth, the survey did not have a question to specify the qualification of the pharmacists; different results may be related to a specific qualification as postgraduate levels or Pharm.D.

CONCLUSION

Pharmaceutical innovation is a crucial factor in developing work in healthcare and health services and plays a fundamental role in economic progress. However, there is a lack of information about pharmaceutical innovation among pharmacists and students in Jordan. This study concluded that, despite the positive perceptions and attitudes toward pharmaceutical innovation, a gap in knowledge and practical applications has been identified.

Based on the findings of this study, it is strongly recommended that pharmacists and pharmacy students receive more information about pharmaceutical innovation aspects. This can be established by introducing the “pharmaceutical innovation” topic into the curricula of a B.Sc. of pharmacy programs and continuing education programs. It is believed that increasing awareness about innovation in pharmacy will result in fruitful outcomes for health and the economy.

More support needs to be considered by authorities and policymakers toward the pharmaceutical business establishments to push the wheel of pharmaceutical innovation in Jordan. Financial and logistic provisions, in addition to long-term sustainability plans, are required to increase the enthusiasm of the “innovation sense” among pharmacists. This is expected to increase the potential of getting productive outcomes from pharmaceutical innovation.

AUTHOR CONTRIBUTIONS

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. All the authors are eligible to be an author as per the international committee of medical journal editors (ICMJE) requirements/guidelines.

FUNDING

There is no funding to report.

CONFLICTS OF INTEREST

The authors report no financial or any other conflicts of interest in this work.

ETHICAL APPROVALS

The protocol of this study was approved by the IRB of the Hashemite University, Jordan (reference number: 4/2019/2020, 22nd Jan 2020 – No.4).

DATA AVAILABILITY

All data generated and analyzed are included within this research article.

PUBLISHER’S NOTE

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

REFERENCES

Akkari ACS, Munhoz IP, Tomioka J, Santos N, Santos RD. Pharmaceutical innovation: differences between Europe, USA and ‘pharmerging’ countries. Gestão & Produção, 2016; 23:365–80.
Alsharif NZ. The need for disruptive innovation in pharmacy. Am J Pharm Educ, 2019; 83(10), 837719; doi:10.5688/ajpe837719
Al-Wazir M, Albsoul-Younes A. Pharmacy in Jordan. Am J Health Syst Pharm, 2005; 62:2548–51.
Al Bawab AQ, AlQahtani F, McElnay J. Health care apps reported in newspapers: content analysis. JMIR mHealth uHealth, 2018; 6:e10237.
Alawi R, Alabbadi I. Investigating the effect of data exclusivity on the pharmaceutical sector in Jordan. Jordan J Pharm Sci, 2015; 8:70–81.
Arruda A. An ethical obligation to use artificial intelligence: an examination of the use of artificial intelligence in law and the model rules of professional responsibility. Am J Trial Advoc, 2016 40:443.
Atkinson R, Wial H. Boosting productivity, innovation, and growth through a National Innovation Foundation. The Information Technology and Innovation Foundation, Washington, DC, 2008.
The Arab Innovation Network, Be the solution competition. The Arab Innovation Network (AIN), England and Wales, UK, 2020.

Baregheh A, Rowley J, Sambrook S. Towards a multidisciplinary definition of innovation. Manag Decis, 2009; 47(8).

Berchtold A. Test–retest: agreement or reliability? Methodol Innov, 2016; 9:205979911667287.

Berger M, Murugi J, Buch E, Isselmuilen C, Moran M, Guzman J, Devlin M, Kubata B. Strengthening pharmaceutical innovation in Africa. Council on Health Research for Development (COHRED), New Partnership for Africa’s Development (NEPAD) 2009. 2010 Council on Health Research for Development (COHRED) New Partnership for Africa’s Development (NEPAD), Geneva, Switzerland, 2016.

Bolarinwa O. Principles and methods of validity and reliability testing of questionnaires used in social and health science researches. Niger Postgrad Med J, 2015; 22:195.

Hakeem Academy. Hakeem academy annual competition (HAAC), Amman, Jordan, 2020.

Dandan MM. Government expenditures and economic growth in Jordan, vol. 4. In International Conference on Economics and Finance Research, Singapore. City. pp 467–71, 2011.

Degroot AM, Dannenburg L, Vanhelling J. Forward and backward word translation by bilinguals. J Memory Lang, 1994; 33:600–29.

Dubois P, De Mouzon O, Scott-Morton F, Seabright P. Market size and pharmaceutical innovation. RAND J Econ, 2015; 46:844–71.

Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009. Health Policy Technol, 2014b; 3:36–58.

Lichtenberg FR, Tatar M, Çalışkan Z. The impact of pharmaceutical innovation on health outcomes and utilization in Turkey: a re-examination. Health Policy Technol, 2017; 6:226–33.

Lichtenberg FR, Tatar M, Çalışkan Z. The impact of pharmaceutical innovation on health outcomes and utilization in Turkey: a re-examination. Health Policy Technol, 2017; 6:226–33.

Odeh M, Amer R, Al Bawab AQ, Kearney MC, Alzoubi KH. Pharmaceutical innovation: The gap between knowledge, attitude, and perceptions among pharmacists and final-year pharmacy students. J Appl Pharm Sci, 2022; 12(10):088–098.

Sampat BN, Lichtenberg FR. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs, 2011; 30:332–9.

Sams-Dodd F. Optimizing the discovery organization for innovation. Drug Discov Today, 2005; 10:1049–56.

Shneiderman B, Leavitt M. Research-based web design & usability guidelines. Department of Health and Human Services, Washington DC, 2006.

Soriano DR, Huang K-H. Innovation and entrepreneurship in knowledge industries. J Bus Res, 2013; 66:1964–9.

Taherdoost H. Validity and reliability of the research instrument; how to test the validation of a questionnaire/survey in a research. How to test the validation of a questionnaire/survey in a research, Jaipur, India, 2016.

Toner M, Tompkins RG. Invention, innovation, entrepreneurship in academic medical centers. Surgery, 2008; 143:168–71.